Clinical trials: Neoadjuvant Non-Small Cell Lung Cancer
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma.
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
- Trial name
- NCT07622706
- Testing
- Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks.
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
NSCLC (Non-small Cell Lung Cancer), EGFR
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
- Trial name
- NCT07807722
- Testing
- Firmonertinib combined anlotinib and chemotehrapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hubei Cancer Hospital
Non-Small Cell Lung Cancer, Immunotherapy
Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
- Trial name
- Dupi-Cemi (NCT06743581)
- Testing
- Cemiplimab, Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Small Cell Lung Cancer, Immunotherapy
Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study
The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical…
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy, Thoracic Surgery
- Trial name
- SAVED LUNG (NCT06743555)
- Testing
- Observation without surgery, Standard-of-care surgery
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy
Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
This study intends to conduct a prospective, non-interventional study to compare the survival benefits of different surgical resection patterns for patients with non-small cell lung cancer who have achieved partial response (PR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoadjuvant Immunotherapy, Surgery
- Trial name
- NCT07373899
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
Lattice radiation therapy (LRT) is a spatially fractionated thoracic radiotherapy technique that creates alternating high- and low-dose regions within primary lung tumors and metastatic lymph nodes to strengthen local tumor…
- Conditions
- Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07670715
- Testing
- lattice radiation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer, Neoadjuvant Therapy
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody…
- Conditions
- Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
- Trial name
- NCT07359040
- Testing
- Ivonescimab, PD-1 Inhibitors
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small-Cell Lung Cancer, Neoadjuvant Therapy
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
This study is a multicenter, single-arm Phase II clinical trial, aiming to explore the safety and preliminary efficacy of oral paclitaxel solution combined with immune checkpoint inhibitors as a neoadjuvant regimen in elderly…
- Conditions
- Non-Small-Cell Lung Cancer, Neoadjuvant Therapy, Paclitaxel
- Trial name
- NCT07599163
- Testing
- Paclitaxel Oral Solution
- Volunteers
- 75 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC, Neoadjuvant Therapy
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
China with high incidence of non-small cell lung cancer. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of lung cancer patients was not…
- Trial name
- NCT05882513
- Testing
- Serplulimab and neoadjuvant therapy, surgical resection of lung cancer, Tumour will be Collected from participant. Fate of sample is Destruction after use
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Small Cell Lung Cancer, PET/CT
FAP-targeted PET/NIR in Lung Malignant Tumors
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included.
- Conditions
- Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
- Trial name
- NCT07498933
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Lung Cancer (Non-Small Cell)
Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast…
- Conditions
- Breast Cancer, Lung Cancer (Non-Small Cell), Colorectal Cancer, Physical Activity
- Trial name
- PREDU (NCT07502963)
- Testing
- PREDU Exercise Program, Recommendation Exercise Program
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- University of Vic - Central University of Catalonia
Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
This is an observational, prospective, multicentre and nationwide study. The study enroll resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world.
- Trial name
- REAL-NADIM (NCT05382052)
- Where
- 20 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer, Stage II-IIIA
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and…
- Conditions
- Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
- Trial name
- NCT05775796
- Testing
- Serplulimab and Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Neoadjuvant Therapy, Concurrent Chemoradiotherapy
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Consolidative immunotherapy following concurrent chemoradiotherapy, based on the PACIFIC trial, has become the standard treatment for locally advanced non-small cell lung cancer (LANSCLC), leading to a 5-year survival rate of…
- Conditions
- Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT06734702
- Testing
- Neoadjuvant therapy, Hypo-RT and concurrent chemotherapy, CFRT and concurrent chemotherapy
- Where
- China
- Volunteers
- 497 people
- Sponsor
- Sun Yat-sen University
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Resectable Non-small Cell Lung Cancer, Bispecific Antibody
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study
The advent of immunotherapy has changed the treatment landscape for patients with non-small cell lung cancer. It has become the mainstay of perioperative treatment for patients with resectable non-small cell lung cancer。…
- Conditions
- Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy
- Trial name
- Neoadjuvant (NCT06946836)
- Testing
- AK104
- Volunteers
- 80 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer (NSCLC), Neoadjuvant Immunotherapy
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
- Trial name
- NCT06926179
- Testing
- neoadjuvant immunotherapy
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute